China Biopharmaceuticals (01177.HK): Zanubrutinib tablets approved for market listing

Zhixin Finance News, China Biopharmaceuticals (01177.HK) announced that the group's jointly promoted medication, Zondatinib Tablets (trade name: Senhetu), with Bristol-Myers Squibb has received approval from the China National Medical Products Administration for listing. The medication is used to treat adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received at least one systemic therapy.